The NASDAQ giveth and the NASDAQ taketh away, especially if you're a biotechnology company. While California-based linkurl:Celera Genomics;http://www.the-scientist.com/blog/display/55142/ made it onto the semi-annually updated NASDAQ Biotechnology Index (NBI), Iceland biotech linkurl:deCODE Genetics;http://www.the-scientist.com/blog/display/55089/ was booted off of the NBI after the company's stock price plunged this fall, linkurl:GenomeWeb;http://www.genomeweb.com/issues/news/150778-1.html?CMP=OTC-RSS reported today (Nov. 18). NASDAQ ranks biotech companies in May and September every year. The rankings are based on several criteria, including having at least $100 million in market capitalization, an average daily trading volume of at least 50,000 shares, and a net worth of at least $5 million. The linkurl:current rankings;http://dynamic.nasdaq.com/dynamic/nasdaqbiotech_activity.stm list 145 companies, including heavy hitters linkurl:Amgen Inc.,;http://www.the-scientist.com/article/display/19256/ linkurl:Affymetrix Inc.;http://www.the-scientist.com/news/display/52891/ and linkurl:Invitrogen Corp.;http://www.the-scientist.com/blog/display/55183/ deCODE's stock price dropped to $0.54 last month - below the $1 threshold set for NASDAQ listing. The company was given 180 days to pull that figure up, but as yet has not. One share in deCODE was...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?